Global Fatty Liver Diseases Treatment Market, By Type (Alcoholic and Non-Alcoholic), Treatment (Blood Test, Imaging Procedures, Liver Tissue Examination), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Fatty Liver Diseases Treatment Market Analysis and Size
The wide technological advancements and routine liver function tests are leading in the early detection of fatty liver treatment. The occurrence rate of fatty liver disease mainly non-alcoholic liver disease (NAFLD) was expected to increase around by 20 to 25% in the coming years. In U.S. it is projected that more than 15 million people are involved in the abuse or over abuse of alcohol and among them more than 90% people suffer from fatty liver disease. The overall market is witnessing a huge growth during the forecast period.
Data Bridge Market Research analyses a growth rate in the fatty liver diseases treatment market in the forecast period 2023-2030. The expected CAGR of fatty liver diseases treatment market is tend to be around 15% in the mentioned forecast period. The market was valued at USD 9.15 billion in 2022, and it would grow up to USD 28 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Fatty Liver Diseases Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Alcoholic and Non-Alcoholic), Treatment (Blood Test, Imaging Procedures, Liver Tissue Examination), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc (U.S.), AbbVie.Inc (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Sun Pharmaceutical Industries Ltd (India), Mylan N.V. (U.S.), Novartis AG (Switzerland), Lupin (India), Cipla Inc (India), Aurobindo Pharma (India), Takeda Pharmaceutical Company Limited (Japan), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (U.S.), PT. Daewoong Pharmaceutical Company (South Korea), Cardax, Inc (Hawaii)
|
|
Market Opportunities
|
|
Market Definition
Fatty liver diseases are typically characterized by accumulated extra fat in the liver. The consumption of alcohol, to a large extent, build up the formation of fatty acids inside human liver cells and is thus called alcoholic liver fatty liver diseases. The prevention of fatty liver includes reducing the risk factors of obesity and adopting healthy lifestyles. Common symptoms include loss of appetite, fatigue, nose bleeds, itchy skin, weight loss, weakness, and abdominal pain, swelling of legs, abdominal swelling and breast enlargement in men.
Global Fatty Liver Diseases Treatment Market Dynamics
Drivers
- Increased Incidence of Alcohol Abuse Cases
The increasing prevalence of people with an overdose of alcohol worldwide is majorly responsible for boosting the growth of the global fatty liver diseases treatment market. As per the records of the 2019 National Survey on Drug Use and Health (NSDUH), 85.6 % of people ages 18 and older stated that they drank alcohol at some point in their lifetime. Thus, it boosts the market growth.
- Growth in Cardiovascular Diseases
As per the records of the WHO, about 60% - 85% of the population have adopted a sedentary life. According to CDC, roughly 31 million adults aged over 50 years live a sedentary life, and only 1 out of 4 U.S. adults meet the appropriate need of physical activity. This helps in the market growth.
Opportunities
- Rising R&D Activities by Several Organizations
The growing research and development activities for the treatment of chronic liver diseases is projected to drive the market growth during the forecast period. For instance, in January 2022, Madrigal Pharmaceuticals, Inc. announced positive top line clinical data from the placebo-controlled, double-blind portion of its phase 3 MAESTRO-NAFLD (non-alcoholic fatty liver disease) safety study of resmetirom. Thus, the market is expected to drive in the forecast period.
- Increasing Demand for Hospitals
The presence of a large number of hospitals in the U.S., along with a well-developed healthcare infrastructure, is another factor contributing to market growth. For instance, as per the American Hospital Association, there were around 6,090 community hospitals, 208 federal government hospitals, and 625 nonfederal psychiatric hospitals in the U.S. Major increase in the number of hospitals and hospital admissions for fatty liver diseases treatment is boosting the market growth.
Restraints/Challenges
- Lack of Drug Approvals
The extreme lack of drug approvals by authorized organizations is hindering market growth. There are no FDA-approved drugs to treat non-alcoholic fatty liver disease (NAFLD) and NASH. Furthermore, the availability of alternative treatment procedures such as organ transplantation and liver resection, are also projected to limit market growth.
- High Cost
The huge expenditure associated with these agents hamper the market growth. Diagnostic procedures including imaging procedures and liver tissue examination, impede the market's growth.
This fatty liver diseases treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the fatty liver diseases treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Fatty Liver Diseases Treatment Market Scope
The fatty liver diseases treatment market is segmented on the basis of type, treatment, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Alcoholic
- Non-Alcoholic
Treatment
- Blood Test
- Imaging Procedures
- Liver Tissue Examination
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Fatty Liver Diseases Treatment Market Regional Analysis/Insights
The fatty liver diseases treatment market is analyzed and market size insights and trends are provided by type, treatment, distribution channel and end-user as referenced above.
The major countries covered in the fatty liver diseases treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Europe has witnessed the highest growth for fatty liver diseases treatment market throughout the forecasted period due to the increased new research and developments.
North America dominates the market due to the presence of key manufacturers of the product is high and, increasing research and development activities.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Fatty Liver Diseases Treatment Market Share Analysis
The fatty liver diseases treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to fatty liver diseases treatment market.
Key players operating in the fatty liver diseases treatment market include:
- Pfizer Inc (U.S.)
- Abbvie,Inc (U.S.)
- Endo International plc (Ireland)
- Teva Pharmaceutical Industries Ltd (Israel)
- Mylan N.V. (U.S.)
- Novartis AG (Switzerland)
- Lupin (India)
- Cipla Inc (India)
- Aurobindo Pharma (India)
- Takeda Pharmaceutical Company Limited (Japan)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Abbott (U.S.)
- PT. Daewoong Pharmaceutical Company (South Korea)
- Cardax, Inc (Hawaii)
SKU-